Source-grounded facts extracted from CASTLE BIOSCIENCES INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
CASTLE BIOSCIENCES INC shareholders approved Approval of the Company’s Non-Employee Director Compensation Policy at the 2026-05-28 meeting.
“Proposal 4. Approval of the Company’s Non-Employee Director Compensation Policy The Company’s stockholders approved the Company’s non-employee director compensation policy as described in the Proxy Statement. The final voting results are as follows: For Against Abstain Broker Non-Votes 21,394,330 1,130,133 48,968 2,415,788”
CASTLE BIOSCIENCES INC shareholders approved Approval of the Compensation of the Company’s Named Executive Officers at the 2026-05-28 meeting.
“Proposal 3. Approval of the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on April 8, 2026 (the “Proxy Statement”). The final voting results are as follows: For Against Abstain Broker Non-Votes 21,280,180 1,281,394 11,857 2,415,788”
CASTLE BIOSCIENCES INC shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2026-05-28 meeting.
“Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection of KPMG LLP by the Audit Committee of the Company’s Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows: For Against Abstain 24,531,366 445,666 12,187”
CASTLE BIOSCIENCES INC shareholders approved Election of Class I Directors at the 2026-05-28 meeting.
“Proposal 1. Election of Directors The Company’s stockholders elected the three individuals listed below as Class I Directors, each to serve until the Company’s 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The final voting results are as follows: For Withhold Broker Non-Votes Ellen Goldberg 15,455,265 7,118,166 2,415,788 Miles D. Harrison 15,607,369 6,966,062 2,415,788 Tiffany P. Olson 14,380,655 8,192,776 2,415,788”
CASTLE BIOSCIENCES INC reported first quarter ended March 31, 2026 results: revenue $83.7 million, net income $14.5 million, EPS $0.49. Guidance raised.
“Castle Biosciences Reports First Quarter 2026 Results Delivered Q1 2026 revenue of $83.7 million”
CASTLE BIOSCIENCES INC: Adopted amended and restated bylaws effective August 5, 2025, with multiple changes including stockholder meeting procedures, quorum thresholds, and nomination requirements (effective 2025-08-05).
“On August 5, 2025, the board of directors (the “Board”) of Castle Biosciences, Inc. (the “Company”) adopted amended and restated bylaws of the Company (as amended and restated, the “A&R Bylaws”), effective as of such adoption date.”
CASTLE BIOSCIENCES INC: Amended and restated certificate of incorporation to add Article IX providing for exculpation of officers as permitted by Delaware law (effective 2025-05-22).
“On May 22, 2025, the Company filed the A&R Charter with the Secretary of State of the State of Delaware, which became effective upon filing.”
CASTLE BIOSCIENCES INC reported the first quarter ended March 31, 2024 results: revenue $73.0 million, net income Net loss... was $2.5 million. Guidance raised.
“such filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Castle Biosciences Reports First Quarter 2024 Results Q1 2024 revenue increased 74% over Q1 2023 to $73 million Q1 2024 total test reports increased 40% over Q1 2023 Raising full-year 2024 revenue guidance to $ 255-265 million from $235-240 million Conference call and webcast today at 4:30”
CASTLE BIOSCIENCES INC entered into Loan and Security Agreement with Silicon Valley Bank, a division of First-Citizens Bank & Trust Company valued at $10.0 million aggregate principal amount of term loans (effective 2024-03-26).
“On March 26, 2024 (the “Closing Date”), Castle Biosciences, Inc., a Delaware corporation (the “Company”), entered into a Loan and Security Agreement (the “Loan Agreement”), by and between the Company, its wholly owned subsidiary, Castle Narnia Real Estate Holding 1, LLC (“Narnia”) and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company (the “Lender”).”
Rodney Cotton was appointed as Class II Director at CASTLE BIOSCIENCES INC.
“On March 26, 2024, following the recommendation of the nominating and corporate governance committee of the Board, the Board increased the size of the Board from eight to nine members and appointed Rodney Cotton to serve as a Class II director with a term ending at the 2024 Annual Meeting.”
Mara G. Aspinall departed as Director at CASTLE BIOSCIENCES INC.
“On March 26, 2024, Mara G. Aspinall notified the Company that she will not to stand for re-election to the board of directors (the “Board”) of the Company at the expiration of her current term at the Company’s 2024 Annual Meeting of Stockholders (the “2024 Annual Meeting”).”
CASTLE BIOSCIENCES INC reported the fourth quarter and year ended December 31, 2023 results: revenue $219.8 million, net income $57.5 million.
“in such filing to this Current Report on Form 8-K. --- EX-99.1 (EX-99.1) --- Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results Full-year 2023 revenue of $220 million, an increase of 60% compared to 2022 and above previously reported guidance Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash,”
CASTLE BIOSCIENCES INC reported the fourth quarter and year ended Dec. 31, 2023 results: revenue more than $210 million.
“contains --- EX-99.2 (EX-99.2) --- Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2023 Results Expect to deliver 2023 total revenue of more than $210 million, at least 53% growth over 2022 Delivered 70,429 total test reports in 2023, an increase of 59% compared to 2022 Year-end 2023 cash, cash equivalents and marketable investment”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.